| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NRIP2 |
| Uniprot No | Q9BQI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-281aa |
| 氨基酸序列 | MLFIFPLSLP WRPSCWKESC STGQRQAGRS REDSVTPPPS SPWPTPPAGA MSTKQEARRD EGEARTRGQE AQLRDRAHLS QQRRLKQATQ FLHKDSADLL PLDSLKRLGT SKDLQPRSVI QRRLVEGNPN WLQGEPPRMQ DLIHGQESRR KTSRTEIPAL LVNCKCQDQL LRVAVDTGTQ YNRISAGCLS RLGLEKRVLK ASAGDLAPGP PTQVEQLELQ LGQETVVCSA QVVDAESPEF CLGLQTLLSL KCCIDLEHGV LRLKAPFSEL PFLPLYQEPG Q |
| 预测分子量 | 31,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于NRIP2重组蛋白的模拟参考文献示例(注：文献信息为虚构演示，实际研究请通过学术数据库检索)：
---
1. **文献名称**: *"Recombinant NRIP2 facilitates Wnt/β-catenin signaling by stabilizing LRP6"*
**作者**: Zhang Y. et al.
**摘要**: 本研究通过原核系统表达重组NRIP2蛋白，证明其通过结合LRP6受体增强Wnt信号传导，并解析了NRIP2的C端结构域在此过程中的关键作用。
2. **文献名称**: *"Structural characterization of NRIP2 and its interaction with nuclear receptors"*
**作者**: Chen L. et al.
**摘要**: 利用昆虫细胞系统表达重组NRIP2.通过X射线晶体学解析其三维结构，发现其通过α-螺旋结构与PPARγ等核受体结合，调控靶基因转录。
3. **文献名称**: *"NRIP2 recombinant protein as a therapeutic target in metabolic syndrome"*
**作者**: Wang X. et al.
**摘要**: 开发了高纯度重组人NRIP2蛋白，并通过体外实验验证其通过抑制mTOR通路改善胰岛素抵抗，为代谢性疾病治疗提供潜在靶点。
---
建议通过 **PubMed** 或 **Web of Science** 以 "NRIP2 recombinant protein" 或 "NRIP2 expression and function" 为关键词检索真实文献。实际研究中，NRIP2(Nuclear Receptor Interacting Protein 2)常与核受体(如PPARγ、ER)及代谢调控通路相关。
NRIP2 (Nuclear Receptor Interaction Protein 2), also known as receptor-interacting protein 140 (RIP140), is a transcriptional coregulator that plays a multifaceted role in nuclear receptor-mediated gene regulation. Initially identified as a coactivator for estrogen receptors, it was later found to interact with various nuclear receptors, including thyroid hormone receptors, PPARs, and LXRs, modulating their transcriptional activity. Structurally, NRIP2 contains multiple LXXLL motifs critical for nuclear receptor binding and repression domains that recruit histone deacetylases (HDACs) or other chromatin-modifying enzymes. Unlike classical coactivators, NRIP2 exhibits context-dependent functions—acting as both a coactivator and corepressor depending on cellular conditions and target genes.
This protein is highly expressed in metabolic tissues (e.g., adipose, liver) and reproductive systems, where it regulates energy homeostasis, lipid metabolism, and ovarian function. Studies highlight its role in suppressing mitochondrial biogenesis and oxidative metabolism through PGC-1α inhibition, linking it to insulin resistance and adipogenesis. Knockout mouse models demonstrate improved glucose tolerance and reduced fat accumulation, suggesting its therapeutic potential in metabolic disorders.
Recombinant NRIP2 protein, typically produced in E. coli or mammalian expression systems with affinity tags (e.g., His-tag, GST-tag), enables in vitro studies of protein-nuclear receptor interactions, post-translational modifications (phosphorylation, SUMOylation), and structural analyses. Its applications span drug discovery for metabolic diseases, cancer research (as NRIP2 overexpression correlates with tumor progression), and reproductive biology investigations. Recent research also explores its non-genomic roles in cytoplasmic signaling pathways, expanding its biological significance beyond transcriptional regulation.
×
